RAPIDO 试验中预测直肠癌全程新辅助治疗或放化疗后肠道毒性的 NTCP 模型
基于 RAPIDO 三期试验,分别针对短程放疗后巩固化疗的 TNT 组和放化疗的 CRT 组,使用 EMBRACE 肠袢和 RTOG 肠袋两种勾画定义构建正常组织并发症概率模型。剂量参数可预测急性腹泻,CRT 组模型性能优于 TNT 组,两种勾画均可用于计划优化。
要点
- 剂量参数可预测 TNT 和 CRT 后的急性腹泻,CRT 组预测性能更优
- CRT 组剂量参数与晚期腹泻 grade ≥1 相关,TNT 组未观察到此关联
- EMBRACE 肠袢和 RTOG 肠袋两种勾画均可用于治疗计划优化
核心结论
- 所评估的剂量参数能够预测基于短程放疗的 TNT 和 CRT 后的急性腹泻,以及 CRT 后的晚期腹泻。
- 模型性能在 CRT 组优于 TNT 组。
- EMBRACE 肠袢和 RTOG 肠袋两种肠道勾画均可用于指导治疗计划优化。
研究设计与样本
- 基于 RAPIDO 三期试验,局部晚期直肠癌患者接受短程放疗(SCRT,5×5 Gy)后巩固化疗(TNT 组)或放化疗(CRT 组)加可选术后化疗。
- 分别针对 TNT 组和 CRT 组,使用 EMBRACE 和 RTOG 两种肠道勾画定义构建正常组织并发症概率模型。
- TNT 组评估剂量参数为 V10Gy、V15Gy、V20Gy,CRT 组为 V15Gy、V30Gy、V40Gy。
- 终点包括急性腹泻 grade ≥2、术前化疗不依从、晚期腹泻 grade ≥1 和患者报告的晚期腹泻。
- 采用单变量和多变量逻辑回归评估关联,以 AUC 和校准图评估模型性能。
主要发现
- TNT 组急性毒性、晚期腹泻 grade ≥1、患者报告晚期腹泻的合格患者数分别为 309、221、209;CRT 组分别为 279、191、190。
- 急性腹泻 grade ≥2 在 TNT 组报告率为 38%,CRT 组为 28%。
- TNT 组所有剂量参数与急性腹泻 grade ≥2 关联的 P 值范围为 .003 至 .08,交叉验证 AUC 为 0.48 至 0.61。
- CRT 组所有剂量参数与急性腹泻 grade ≥2 关联的 P 值范围为 <.001 至 .03,交叉验证 AUC 为 0.56 至 0.67。
- CRT 组观察到剂量参数与晚期腹泻 grade ≥1 的关联。
关键数值与推荐
- TNT 组评估 V10Gy、V15Gy、V20Gy;CRT 组评估 V15Gy、V30Gy、V40Gy。
- 急性腹泻 grade ≥2 在 TNT 组为 38%,CRT 组为 28%。
- TNT 组 P 值 .003–.08,交叉验证 AUC 0.48–0.61;CRT 组 P 值 <.001–.03,交叉验证 AUC 0.56–0.67。
- 所有模型校准 reasonably well。
临床怎么用
- 可利用所评估的剂量参数预测直肠癌 TNT 或 CRT 后的急性腹泻风险。
- CRT 组模型性能更优,可优先用于该人群的毒性预测。
- EMBRACE 肠袢和 RTOG 肠袋两种勾画均可用于治疗计划优化以限制肠道剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radiation-induced bowel toxicity is a frequently observed adverse event after rectal cancer treatment. In the phase 3 Rectal cancer And Preoperative Induction therapy followed by Dedicated Operation (RAPIDO) trial, patients with locally advanced rectal cancer received either short-course radiation therapy (SCRT, 5 × 5 Gy) with consolidation chemotherapy (total neoadjuvant treatment [TNT] arm) or chemoradiation (CRT) with optional postoperative chemotherapy (CRT arm). We developed normal tissue complication probability models for bowel toxicity after SCRT-based TNT and CRT, using 2 different bowel contour definitions. METHODS AND MATERIALS: Normal tissue complication probability models were developed for each arm separately using the Image guided intensity modulated External beam radiochemotherapy and MRI based adaptive BRAchytherapy in locally advanced CErvical cancer (EMBRACE) and Radiation Therapy Oncology Group (RTOG) bowel contours. Evaluated dose-parameters were the V10Gy, V15Gy, and V20Gy in the TNT and V15Gy, V30Gy, and V40Gy in the CRT arm. Endpoints included acute diarrhea grade ≥2, noncompliance with preoperative chemotherapy, late diarrhea grade ≥1, and patient-reported late diarrhea. Associations were assessed with uni- and multivariable logistic regression models, and model performance with the area-under-the-curve (AUC) and calibration plots. RESULTS: The numbers of eligible patients in the TNT arm were 309 (acute toxicity), 221 (late diarrhea grade ≥1), and 209 (patient-reported late diarrhea), whereas in the CRT arm respective numbers were 279, 191, and 190. Acute diarrhea grade ≥2 was reported in 38% (TNT) and 28% (CRT) of the patients. All dose-parameters (from both bowel contours) showed comparable associations with the endpoint acute diarrhea grade ≥2. In the TNT arm, P-values ranged from .003 to .08 and cross-validated AUCs from 0.48 to 0.61. In the CRT arm, P-values ranged from <.001 to .03 and cross-validated AUCs from 0.56 to 0.67. All models were reasonably well calibrated. In addition, associations were observed between dose-parameters and late diarrhea grade ≥1 in the CRT arm. CONCLUSIONS: The evaluated dose-parameters were able to predict acute diarrhea after SCRT-based TNT and CRT, and late diarrhea after CRT. Model performance was better in the CRT arm than the TNT arm. Both the EMBRACE bowel loop and RTOG bowel bag contour can be used to guide treatment plan optimization.
引用
- Tanaka MD, Janssen TM, Schipaanboord BWK, et al. NTCP Models Predicting Bowel Toxicity After Total Neoadjuvant Treatment or Chemoradiation for Rectal Cancer in the RAPIDO Trial. Int J Radiat Oncol Biol Phys. 2026. PMID: 42556586. doi:10.1016/j.ijrobp.2026.07.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。